Pfizer and Medivation to Co-Develop and Market Alzheimer’s and Huntington’s Treatment
Pfizer Inc. (New York, NY) and Medivation, Inc. (San Francisco, CA) have joined forces to develop and commercialize Dimebon, Medivation’s investigational drug for treating Alzheimer’s disease and Huntington’s disease.
Pfizer Inc. (New York, NY) and Medivation, Inc. (San Francisco, CA) have joined forces to develop and commercialize Dimebon, Medivation’s investigational drug for treating Alzheimer’s disease and Huntington’s disease. Dimebon is currently being evaluated in an international, confirmatory Phase 3 trial in patients with mild-to-moderate Alzheimer’s disease (www.connectionstudy.com).
Under the terms of the agreement, Medivation will receive an up front cash payment of $225 million. Medivation and Pfizer will collaborate on the Phase 3 program in Alzheimer’s disease, Huntington’s disease, and regulatory filings in the United States. The companies will share all US development and commercialization expenses along with US profits/losses on a 60/40% basis, with Pfizer assuming the larger share of both expenses and profit/losses. In addition, Medivation will co-promote Dimebon to specialty physicians in the US.
Pfizer will have the responsibility for development, regulatory, and commercialization outside the US and will pay Medivation tiered royalties on commercial sales outside of the US.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
